In particular, high PVT1, or high MYC predicted shorter leukemia-free survival in t(8;21) AML patients [43], which suggested a potential mechanism of chemotherapy resistance in cells with leukemia initiating capacity, that drives disease progression. Here, PVT1 is linked to acute myeloid leukemia.